Urothelial Carcinoma
352
80
123
113
Key Insights
Highlights
Success Rate
69% trial completion
Published Results
58 trials with published results (16%)
Research Maturity
113 completed trials (32% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
14.5%
51 terminated out of 352 trials
68.9%
-17.7% vs benchmark
5%
18 trials in Phase 3/4
51%
58 of 113 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 113 completed trials
Clinical Trials (352)
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
A Study of GEN1106 in Participants With Solid Tumors
JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
DBC-664 in Adult Patients With Solid Tumors
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors